Financhill
Sell
10

NVO Quote, Financials, Valuation and Earnings

Last price:
$69.47
Seasonality move :
4.94%
Day range:
$66.88 - $69.63
52-week range:
$69.18 - $148.15
Dividend yield:
2.09%
P/E ratio:
21.11x
P/S ratio:
7.35x
P/B ratio:
15.37x
Volume:
5.8M
Avg. volume:
7.5M
1-year change:
-45.92%
Market cap:
$307.6B
Revenue:
$42.1B
EPS (TTM):
$3.28

Earnings Data

Next earnings date for NVO
May 07
2025
Most recent earnings per share
$0.91
Beat by $0.10
(Feb 5/2025)
Consensus Estimate
$0.80
(Feb 5/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

NVO Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
06/30/2025 Q2 $11.8B -- -- $0.85 --
05/07/2025 Q1 $11.4B -- -- $0.89 --
02/05/2025 Q4 $11.5B $12.2B $0.91 $0.80 $0.10
11/06/2024 Q3 $10.5B $10.5B $0.90 $0.86 $0.04
08/07/2024 Q2 $10.1B $9.8B $0.65 $0.71 -$0.06
05/02/2024 Q1 $9.1B $9.5B $0.83 $0.77 $0.05
01/31/2024 Q4 $8.9B $9.5B $0.71 $0.65 $0.06
11/02/2023 Q3 $8.1B $8.6B $0.73 $0.66 $0.07
08/10/2023 Q2 $8.2B $7.9B $0.63 $0.66 -$0.03
05/04/2023 Q1 $7.7B $7.7B $0.63 $0.59 $0.04
02/02/2023 Q4 $6.9B $6.6B $0.41 $0.46 -$0.05
11/02/2022 Q3 -- $6.2B $0.43 -- --
08/04/2022 Q2 -- $5.9B $0.42 -- --
05/12/2022 Q1 -- $6.3B $0.47 -- --
02/02/2022 Q4 -- $5.9B $0.37 -- --
11/03/2021 Q3 -- $5.6B $0.42 -- --
08/04/2021 Q2 -- $5.4B $0.43 -- --
05/05/2021 Q1 -- $5.5B $0.44 -- --
02/03/2021 Q4 -- $5.1B $0.32 -- --
10/30/2020 Q3 -- $4.9B $0.35 -- --
08/06/2020 Q2 -- $4.4B $0.33 -- --
05/06/2020 Q1 -- $5B $0.37 -- --
02/05/2020 Q4 -- $4.8B $0.27 -- --
11/01/2019 Q3 -- $4.5B $0.32 -- --
08/09/2019 Q2 -- $4.5B $0.30 -- --
05/03/2019 Q1 -- $4.5B $0.33 -- --
02/04/2019 Q4 -- $4.5B $0.27 -- --
11/01/2018 Q3 -- $4.3B $0.29 -- --
08/08/2018 Q2 -- $4.4B $0.34 -- --
05/02/2018 Q1 -- $4.4B $0.36 -- --
02/01/2018 Q4 -- $4.4B $0.27 -- --
11/01/2017 Q3 -- $4.2B $0.31 -- --
08/09/2017 Q2 -- $4.2B $0.30 -- --
05/03/2017 Q1 -- $4.1B $0.29 -- --
02/02/2017 Q4 -- $4.3B $0.25 -- --
10/28/2016 Q3 -- $4.1B $0.29 -- --
08/05/2016 Q2 -- $4.2B $0.30 -- --
04/29/2016 Q1 -- $4B $0.27 -- --
02/03/2016 Q4 -- $4.2B $0.24 -- --
10/29/2015 Q3 -- $4B $0.24 -- --
08/06/2015 Q2 -- $4B $0.24 -- --

Novo Nordisk AS Earnings Questions

  • How Much did Novo Nordisk AS Generate in Revenue Last Quarter?

    Novo Nordisk AS reported $12.2B worth of top line sales in its most recent quarter.

  • Did Novo Nordisk AS Beat Earnings Last Quarter?

    Novo Nordisk AS announced earnings per share of $0.91 which represents a beat of analyst forecast a $0.80 per share.

  • Is Novo Nordisk AS Profitable?

    Novo Nordisk AS reported $10.4B that represents $2.33 per share over the last quarter.

  • What is the Analyst Consensus for Novo Nordisk AS EPS Next Year?

    Novo Nordisk AS's earnings are forecast to grow from $3.28 per share to $3.06 per share next year representing an increase of 18.5%.

  • When is Novo Nordisk AS's Earnings Date?

    Novo Nordisk AS's next earnings date is May 7, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Could IBIT Go?
How High Could IBIT Go?

Recently, a surprising number of billionaire hedge fund managers have…

Is Raymond James Stock a Buy, Sell or Hold?
Is Raymond James Stock a Buy, Sell or Hold?

Raymond James Financial (NYSE:RJF) is one of America’s large financial…

Is JHX Stock a Buy Sell or Hold?
Is JHX Stock a Buy Sell or Hold?

James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…

Stock Ideas

Buy
56
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
41
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
80
CORT alert for Apr 1

Corcept Therapeutics [CORT] is up 109.21% over the past day.

Sell
40
RGC alert for Apr 1

Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.

Buy
74
COOP alert for Apr 1

Mr. Cooper Group [COOP] is up 14.4% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock